Optimal tobramycin dosage in patients with cystic fibrosis - Evidence for predictability based on previous drug monitoring

Infection

Volumn 27, Issue 4-5, 1999, Pages 268-271

  Bartel, K ^a   Habash, T ^a   Lugauer, S ^a   Barmeier H ^a   Bowing B ^a   Unsal M ^b   Schoerner, C ^b   Heininger, U ^a,c  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; TOBRAMYCIN;

ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG INFECTION; MALE; PREDICTION; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADULT; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PNEUMONIA, BACTERIAL; PREDICTIVE VALUE OF TESTS; PSEUDOMONAS INFECTIONS; RECURRENCE; RETROSPECTIVE STUDIES; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 0032824382     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s150100050027     Document Type: Article

References (10)

1. De Groot, R., Smith, A. L.: Antibiotic pharmacokinetics in cystic fibrosis. Difference and clinical significance. Clin. Pharmacokinet. 13 (1987) 228-253.
2. Wood, P. J., Ioannides-Demos, L. L., Li, S. C., Williams, T. J., Hickey, B., Spicer, W. J., Hooper, R. E., McLean, A. J.: Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Thorax 51 (1996) 369-373.
3. Hoiby, N.: Antibiotic therapy for chronic infection of Pseudomonas in the lung. Ann. Rev. Med. 44 (1993) 1S-10S.
4. Mann, H. J., Canafax, D. M., Cipolle, R. J., Daniels, C. E., Zaske, D. E., Warwick, W. J.: Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis. Pediatr. Pulmonal. 1 (1985) 238-243.
5. Hsu, M., Aguila, H. A., Schmidt, V. L., Munzenberger, P. J., Kauffman, R. E., Polgar, C.: Individualization of tobramycin dosage in patients with cystic fibrosis. Pediatr. Infect. Dis. 3 (1984) 526-529.
6. Heininger, U., Böwing, B., Stehr, K., Solbach, W.: Aminoglykoside bei Patienten mit Mukoviszidose und pulmonaler Exazerbation: Vergleich von Einmal- und Dreimalgabe. Klin. Pädiatr. 205 (1993) 18-22.
7. McCormack, J. P., Jewwesson, P. J.: A critical re-evaluation of the "therapeutic range" of aminoglycosides. Clin. Infect. Dis. 14 (1992) 320-339.
8. Touw, D. J., Vinks, A. A., Heijerman, H. G., Hermans, J., Bakker, W.: Suggestions for the optimization of the initial tobramycin dose in adolescent and adult patients with cystic fibrosis. Ther. Drug Monit. 16 (1994) 125-131.
9. Thomassen, M. J., Demko, C. A., Doershuk, C. F.: Cystic fibrosis: a review of pulmonary infections and interventions. Pediatr. Pulmonol. 3 (1987) 334-351.
10. Frederiksen, B., Lanng, S., Koch, C., Hoiby, N.: Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr. Pulmonol. 21 (1996) 153-158.